{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:58:00Z","timestamp":1775793480677,"version":"3.50.1"},"reference-count":6,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T00:00:00Z","timestamp":1487980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T00:00:00Z","timestamp":1487980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle Nerve"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1002\/mus.25529","type":"journal-article","created":{"date-parts":[[2016,12,25]],"date-time":"2016-12-25T04:46:24Z","timestamp":1482641184000},"page":"328-330","source":"Crossref","is-referenced-by-count":33,"title":["QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis"],"prefix":"10.1002","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-8617","authenticated-orcid":false,"suffix":"Jr","given":"James F.","family":"Howard","sequence":"first","affiliation":[{"name":"Department of Neurology; University of North Carolina; 2200 Physicians Office Building, CB 7025, 170 Manning Drive Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Freimer","sequence":"additional","affiliation":[{"name":"Department of Neurology; Ohio State University; Columbus Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Medical Science and Development Operations, Alexion Pharmaceuticals; New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Science and Development Operations, Alexion Pharmaceuticals; New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Collins","sequence":"additional","affiliation":[{"name":"Connexion Healthcare; Newtown Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Kissel","sequence":"additional","affiliation":[{"name":"Department of Neurology; Ohio State University; Columbus Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the MG (Phase2) Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,25]]},"reference":[{"key":"10.1002\/mus.25529-BIB0001|mus25529-cit-0001","volume-title":"The Quantitative Myasthenia Gravis (QMG) Test: the manual","author":"Barohn","year":"2000"},{"key":"10.1002\/mus.25529-BIB0002|mus25529-cit-0002","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/mus.25529-BIB0003|mus25529-cit-0003","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25529-BIB0004|mus25529-cit-0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25529-BIB0005|mus25529-cit-0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mus.24953","article-title":"The best of both worlds: using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis","volume":"53","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25529-BIB0006|mus25529-cit-0006","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"}],"container-title":["Muscle & Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.25529","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/mus.25529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T04:06:40Z","timestamp":1625458000000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.25529"}},"subtitle":["Short Reports"],"short-title":[],"issued":{"date-parts":[[2017,2,25]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"URL":"https:\/\/doi.org\/10.1002\/mus.25529","archive":["Portico"],"relation":{},"ISSN":["0148-639X"],"issn-type":[{"value":"0148-639X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2,25]]}}}